Characterisation of VP-16-induced DNA cleavage in oestrogen-stimulated human breast cancer cells. by Epstein, R. J. et al.
Br. J. Cancer (1988), 57, .5-450 © The Macmillan Press Ltd., 1988
Characterisation of VP-16-induced DNA cleavage in
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Summary Cycling cells are recognised to be more susceptible than quiescent cells to the cytotoxic action of
many commonly used cancer chemotherapeutic agents. We have found that oestrogen stimulation of T-47D
human breast cancer cells is accompanied by a two-fold increase in VP-16-induced DNA cleavage as
measured by alkaline DNA unwinding, and that this increase in DNA cleavage is accompanied by a
corresponding enhancement of drug-induced cytostasis. The enhancement of VP-16-induced DNA cleavage
seen with oestrogen exposure is antagonised both by antioestrogen treatment and by cycloheximide, an
inhibitor of protein synthesis, but not by the DNA synthesis inhibitor aphidicolin. Increased c-myc protein
synthesis is detectable within an hour of oestrogen exposure, while increased VP-16-induced DNA cleavage is
detectable within 4h and increased DNA synthesis within 16h. Only small changes in cell-cycle distribution
occur with oestrogen stimulation. In the absence of VP-16, oestrogen does not reduce DNA double-
strandedness, nor does it induce changes in chromatin structure as measured by alterations in DNA
superhelicity or chromatin accessibility. These findings suggest that oestrogen enhances VP-16-induced DNA
damage in asynchronously growing Gl-phase cells and that this enhancement may be dependent at some
point upon de novo protein synthesis. Oestrogen pre-treatment of T-47D human breast cancer cells improves
the therapeutic index of VP-16 without the need for cell synchronisation or highly precise drug scheduling.
Oestrogen stimulation potentiates the cytotoxicity of S-
phase-active drugs in synchronised human breast cancer cells
in vitro (Weichselbaum et al., 1978). DNA cleavage induced
by non-phase-specific drugs such as m-AMSA has also been
reported to be enhanced by oestrogen 'priming' of un-
synchronised human breast cancer cell cultures (Zwelling et
al., 1983), but the extent to which this DNA cleavage is
reponsible for cytotoxicity remains uncertain. Moreover, it is
not known whether such enhancement of DNA cleavage
reflects changes in chromatin structure induced by oestrogen,
such as changes in accessibility of chromatin to drug
interaction (Kuo, 1981) or changes in DNA superhelicity
(Lipetz et al., (1982).
Clinical trials using tamoxifen synchronisation and sub-
sequent oestrogenic 'recruitment' prior to cytotoxic therapy
of breast cancer have been undertaken (Eisenhauer et al.,
1984; Lippman et al., 1984; Paridaens et al., 1985; Conte et
al., 1987) but have so far failed to demonstrate any signifi-
cant overall survival benefit (Davidson & Lippman, 1987).
Part of the difficulty in applying this strategy successfully in
vivo may relate to optimal scheduling of cytotoxic therapy
(especially S-phase-specific drugs) and reversal of tamoxifen-
induced cytostasis (Furr & Jordan, 1984). Here we report
our findings using oestrogen priming of unsynchronised T-
47D human breast cancer cells prior to VP-16 treatment, and
show that this results in enhanced DNA cleavage which
occurs independently of enhanced DNA synthesis or
measurable chromatin modification, and which is also
accompanied by enhanced toxicity.
Materials and methods
Cell culture, hormone stimulation and cell growth
T-47D cells were obtained from the American Type Culture
Collection (Rockville, MD) in their 84th passage. Cell stocks
were maintained as monolayer cultures in RPMI plus 10%
foetal calf serum, glutamine and antibiotics (subsequently
referred to as complete medium) and incubated at 37°C in
5% CO2 in air. For three weeks prior to experiments
involving hormone stimulation, cells were cultured in
medium supplemented with 5% dextran-charcoal-stripped
srum (Reddel et al., 1984) unless stated otherwise; cells were
able to be passaged in this oestrogen-deprived medium for
over six months without reduction in plating efficiency. 17-fl-
oestradiol was added to cultures at a final concentration of
10-8 M in 0.1% ethanol 24h prior to experiments unless
specified otherwise, while control samples received ethanol
alone. 4-hydroxytamoxifen (a gift of Dr A.H. Todd, ICI plc
Macclesfield, UK) was added simultaneously with oestrogen
at a concentration of 10-7 M. For growth curves, cells were
detached using trypsin/EDTA and counted in triplicate using
a Coulter counter. Cytotoxicity was measured using the
growth delay method validated by Leonessa et al. (1986) in
which cells are grown for five days in complete medium
following experimental treatment.
Drug treatment
VP-16 was stored as a light-protected 34mM stock at room
temperature. Bleomycin sulphate was a gift of Lundbeck Ltd
(Luton, Beds UK). Following pre-treatment of samples with
either oestrogen or ethanol, drugs were diluted in water and
added to samples at various concentrations for 1 h at 370C.
Following removal of treated medium, monolayers were
washed twice in PBS and then either frozen (using 10mM
Tris-HCl, 100mM NaCl, 10mM EDTA, 1 mgml-1 bovine
serum albumin, pH 8.0; for alkaline DNA unwinding assays)
or re-fed with complete medium (for growth curves).
Colcemid (60ngml-1) was used for stathmokinetic ex-
periments. For experiments involving cycloheximide,
oestrogen was added to samples for 6h only prior to VP-16
exposure; designated samples received cycloheximide
10 gml-1 at the same time as oestrogen administration.
Aphidicolin (0.25ygml-1) was added to samples at the same
time as oestrogen for 24h prior to VP-16 exposure, and flow
cytometry confirmed the induction of G1-S arrest in
aphidicolin-treated samples.
DNA damage assays
(a) Alkaline unwinding This technique quantifies DNA clea-
vage as a time-dependent function of DNA unwinding in
alkali, since the rate of DNA unwinding is known to vary
linearly with the amount of pre-existing DNA strand-break-
age (Ahnstrom & Erixon, 1973). DNA unwinding was
determined by fluorometry using a bisbenzamide dye (Latt &
Stetten, 1976). As described previously (Smith et al., 1986),
treated cell monolayers were frozen and then detached by
Correspondence: R.J. Epstein.
Received 5 October 1987; and in revised form, 20 December 1987.
Br. J. Cancer (1988), 57, 445-450 C The Macmillan Press Ltd., 1988446 R.J. EPSTEIN et al.
rapid thawing. Following resuspension in ice-cold buffer,
0.5ml aliquots of the cell suspension were analysed using the
method developed by Kanter & Schwartz (1982). Briefly,
quadruplicate samples were exposed to 0.1 N NaOH for
60min at 4°C and neutralised with 0.1 N HCI. Detergent
buffer (0.16% sodium lauroyl sarcosinate, 0.2M KH2PO4,
0.04M disodium EDTA, pH 7.4) containing Hoechst 33342
at a final concentration of 0.25 M was then added, and the
samples homogenised using a 150W ultrasonic disintegrator.
Fluorescence was measured 24h later using a Perkin-Elmer
MPF-4 spectrofluorimeter. A second set of samples was
processed in parallel except that the alkaline lysates were
subjected to an additional sonication to accelerate DNA
unwinding and thereby permit calculation of background
fluorescence associated with minimal residual DNA double-
strandedness; while a third set of samples was not exposed to
alkali at all, permitting calculation of fluorescence associated
with maximal DNA doublestrandedness. Treatment-induced
enhancement of DNA unwinding was determined by the
expression f= - 100 log (Dx/Dc), where Dx and Dc re-
present the percentage of doublestranded DNA in treated
and control samples respectively. DNA damage induced by
one Gy X-irradiation was consistently detectable, and use of
the algorithm yielded a linear damage-induced response up
to at least 16Gy. X-ray calibration of the assay was used to
determine breaks/109 daltons DNA assuming 0.5 breaks/109
daltons mol. wt./Gy (Kohn et al., 1976).
(b) Nucleoid sedimentation As originally described by Cook
& Brazell (1975) and modified by Farzaneh et al. (1982),
cells were detached and resuspended in cold PBS. Fifty pl of
suspension was then deposited onto 150y1 lysis buffer (final
concentration 2mm EDTA, 0.5% Triton X-100, 100mM
Tris-HCI, 2M NaCl, pH 8.0) over 3.8ml 15-30% sucrose
gradients containing 1mM EDTA, 10mM Tris-HCI, 2M
NaCl and 1pM Hoechst-33342 at pH 8.0. Cells were then
lysed for 30min at room temperature prior to centrifugation
for 30min at 50,000g. For titration experiments designed to
measure the superhelicity of these histone-depleted nucleoid
structures (Lipetz et al., 1982), ethidium bromide was in-
corporated into both the lysis buffer and the sucrose
gradient at the specified concentration in lieu of
Hoechst-33342.
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DNase II treatment
Transcriptionally active chromatin is known to exhibit
increased sensitivity to nuclease-induced DNA nicking (Gazit
& Cedar, 1980). To determine whether oestrogen stimulation
of T-47D cells was associated with any gross change in
chromatin accessibility to nuclease, cells were permeabilised
and detached by freeze-thawing, then resuspended in pre-
warmed buffer (10mM Tris-HCl, 10mM EDTA, 100mM
NaCl, 1 mgml-1 bovine serum albumin, pH 7.75) and
incubated in a 37°C water-bath for 15min with varying
concentrations of DNase II (20 Kunitz units/ml; bovine
spleen type; Sigma). The reaction was stopped by dilution
with ice-cold buffer at pH 8.0 in preparation for the alkaline
unwinding assay.
Tritiated thymidine incorporation
3H-thymidine (specific activity 6.7Cimmol-1; New England
Nuclear, Boston MA) was added to samples at a con-
centration of 0.5pCiml-1 together with either oestrogen or
ethanol for the required period. Cell monolayers were
washed three times in PBS supplemented with magnesium
and calcium, lysed using 4-aminosalicylic acid (6% w/v;
BDH, Poole, Dorset), triisopropylnaphthalenesulphonic acid
(1% w/v; Eastman Kodak, Rochester, NY) and butan-2-ol
(6% v/v), then removed with a rubber policeman, mixed
with trichloroacetic acid (10% w/v) and the acid-insoluble
radioactivity isolated on glass fibre filters. The filters were
mixed with 10mls scintillant before being counted with a
single-channel ratio programme and converted to dis-
integrations per minute using a chloroform quench curve.
C-myc protein synthesis
The ELISA assay developed by Moore & Evan (1987) was
used. Briefly, pan-myc (antibody was adsorbed to microtitre
wells. Cell monolayers were washed with PBS containing
0.02% EDTA and 0.1% sodium azide and then removed
using a rubber policeman. Cells were centrifuged,
resuspended at a density of 5 x 107 cellsml-1, and lysed.
Lysates were prepared by boiling cells in SDS and 50mM
dithiothreitol, alkylating with 100mM iodoacetamide, shear-
ing the DNA by repeated passage through a 26-gauge
needle, and diluting in Nonidet P40. Samples were then
incubated in microtitre plates. A second anti-myc mono-
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Figure 1 Stimulation of T-47D cell growth by oestrogen: (a) Cells maintained in complete medium; (b) Cells deprived of
oestrogen by being incubated in medium supplemented with 5% charcoal-stripped serum for 2 days prior to oestrogen
replenishment; (c) Cells maintained in charcoal-stripped medium for one week prior to oestrogen replacement; (d) Cells maintained
in stripped medium for three weeks prior to oestrogen stimulation. Nx, number of cells counted after 4-8 day's growth in medium
supplemented with 10-8 M 17-B-oestradiol or 0.1% ethanol alone; No, number of cells counted immediately prior to oestrogen/
ethanol addition. 0, control cells; 0, oestrogen-treated cells.
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clonal antibody conjugated to alkaline phosphatase then
recognised captured human myc protein, and bound alkaline
phosphatase was detected colorimetrically. The reaction was
stopped with acid and optical density determined at 494nm.
Flow cytometry
Following trypsin/EDTA detachment, cells were stained with
ethidium bromide 50 ugml-1 plus 0.125% Triton X-100
(Taylor & Milthorpe, 1980) and ribonuclease 0.5mgml-1 for
10min prior to analysis. Samples were monitored using a
flow cytometer incorporating an Innova 70-5 argon laser
(Coherent, Palo Alto, CA) tuned to 488 nm at 200mV. DNA
fluorescence distributions were analysed by computer using a
cell-cycle phase-fitting programme which assumes normal
distributions for GI aand G2M phase populations and
which calculates a probability function for the S phase
distribution based upon the means and standard deviations
of the GI and G2M phase (Watson et al., 1987).
Results
(i) Oestrogen stimulation of T-47D cell growth, VP-16-
induced DNA cleavage and cytostasis
Figure la shows the growth of T-47D cells maintained in
complete medium. No significant enhancement of growth
occurs with oestrogen addition to the medium. In contrast,
the growth rate of cells maintained in oestrogen-deprived
(charcoal-stripped) medium for 2 days (Figure lb), one week
(Figure lc) and 3 weeks (Figure ld) declines progressively
and it then becomes possible to stimulate cell growth with
oestrogen.
In Figure 2, the oestrogen concentration which optimally
stimulates cell growth (represented in Figure 2a as minimal
doubling time) corresponds to the optimal concentration for
enhancement of VP-16-induced DNA cleavage (Figure 2b)
and VP-16-induced cell growth retardation (Figure 2c).
These data suggest a relationship between the growth-
stimulatory effect of oestrogen and the observed en-
hancement of VP-16-induced DNA damage.
(ii) Effect of inhibitors on oestrogen-induced DNA damage
enhancement
Inhibition of the growth-stimulatory effect of oestrogen
using a potent antioestrogen, 4-hydroxytamoxifen, results in
antagonism of the observed enhancement of VP-16-induced
DNA cleavage (Figure 3a). Simultaneous exposure of cells to
oestrogen and the protein synthesis inhibitor, cycloheximide,
also leads to antagonism of this effect (Figure 3b). However,
inhibition of DNA synthesis using the DNA polymerase
inhibitor aphidicolin does not affect the enhancement of
DNA cleavage seen in oestrogen-primed cells (Figure 3c).
These findings suggest that the enhancing effect of oestrogen
on VP-16-induced DNA cleavage is mediated at some point
by new protein synthesis but not by entry of cells into DNA
synthesis.
(iii) Influence of oestrogen of DNA doublestrandedness and
chromatin structure
Oestrogen stimulation of up to 72h duration failed to cause
any change in DNA scission as measured by nucleoid
sedimentation (Figure 4a), and similar results were observed
in cells simultaneously treated with the poly(ADP-ribosyl)
transferase inhibitor 3-aminobenzamide (data not shown),
suggesting that oestrogen stimulation alone may not be
associated with either long-lived or transient DNA strand-
break induction. DNA cleavage was also measured by
alkaline unwinding in cells treated with oestrogen for 24h,
and no effect was seen over a 3 h unwinding period (Figure
4a). This implies that pre-existing DNA cleavage in samples
not exposed to drug does not contribute to the observed
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Figure 2 Effect of oestrogen on cell growth, VP-16-induced
DNA cleavage, and VP-16-induced cytostasis in T-47D cells: (a)
Growth stimulatory effect of various oestrogen concentrations.
TDx, population doubling time for oestrogen-treated cells; TDc,
population doubling time for ethanol-treated control cells; (b)
Effect of oestrogen concentration on percentage enhancement of
DNA cleavage induced in samples exposed to 51M VP-16 for
1 h at 37°C when compared to ethanol control. fx, DNA
cleavage in oestrogen-treated samples (see Materials and
methods); fc, DNA cleavage in control samples; (c) Effect of
oestrogen concentration on growth delay induced by 1 h
exposure to 5pM VP-16. Oestrogen-treated samples were
counted in triplicate and expressed as a percentage of control
values following 5 days' growth in complete medium subsequent
to VP-16 treatment. In samples not exposed to VP-16, the total
number of cell doublings following the 5-day incubation in
complete medium consistently differed by <5% between samples
initially pre-treated with either oestrogen or ethanol. Nx, number
of cells in samples incubated in complete medium for five days
following VP-16 exposure; Nc, number of cells in samples
following 5 days' growth in complete medium without VP-16
exposure. 0, control cells; 0, oestrogen-treated cells.
enhancement of VP-16-induced DNA cleavage as assayed by
alkaline DNA unwinding. That oestrogen also does not alter
the overall superhelicity of DNA in T-47D cells is suggested
by Figure 4b, which shows that a similar amount of
ethidium bromide is required to 'untwist' negatively
supercoiled DNA (thereby resulting in minimum
sedimentation) in both oestrogen-treated and control cells.
Chromatin accessibility to drug treatment appears to be
similarly unaffected by oestrogen in either viable (Figure 4c)
or freeze-thaw-permeabilised (Figure 4d) cells, since the
induction of strand-breaks by either bleomycin or DNase II
respectively is unchanged in cells stimulated for 24h.
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Figure 3 Effect of inhibitors on oestrogen-induced DNA cleavage enhancement following VP-16 treatment: (a), 4-hy-
droxytamoxifen 10-7M (24h). 0, control cells; 0, oestrogen-treated cells; A, controls plus 4-hydroxytamoxifen; A, oestrogen-
treated cells simultaneously treated with 4-hydroxytamoxifen; (b) Cycloheximide 0pgml-1 (6h). 0, control cells; 0, oestrogen-
treated cells; A, control cells plus cycloheximide; A, oestrogen-treated (6h) cells plus cycloheximide (6h); (c) Aphidicolin
0.25 pgml-1 (24h). 0, control cells; 0, oestrogen-treated cells; El, control cells plus aphidicolin; *, oestrogen-treated (24h) cells
plus aphidicolin (24h). All data points based on quadruplicate determinations.
(iv) Time-course of events following oestrogen stimulation
Synthesis of c-myc protein peaks after one hour of oestrogen
stimulation, and is maintained at this level for 24h (Figure
Sa). This final level of c-myc protein in stimulated cells
represents approximately twice that measured in control
cells. The amount of DNA cleavage induced by 5pM VP-16
also reaches double control levels in cells stimulated for 24h,
and - 50% of this increase is achieved within 8 h (Figure
5b). In contrast, no change in tritiated thymidine in-
corporation (Figure 5c), fraction of cells involved in DNA
synthesis (Figure 5d), or rate of cell-cycle traverse (Figure
5e) is measurable after 8h oestrogen stimulation (Figure 5c).
This sequence of events suggests that oestrogen-induced
mitogenesis per se is preceded by very early changes in
protein (such as c-myc) synthesis, and that the observed
enhancement of VP-16-induced DNA cleavage is related to
an intermediate phase of cell activation which precedes
stimulation of DNA synthesis.
Discussion
The finding that oestrogen-stimulated T-47D cells sustain
higher levels of VP-16-induced DNA cleavage (Figure 2b)
and VP-16-induced cytostasis (Figure 2c) than do oestrogen-
deprived cells extends the observation of Sullivan et al.
(1986) that synchronously proliferating cells incur greater
VP-16-induced DNA cleavage and cytotoxicity than do
quiescent cells. Although not conclusive, these findings are
consistent with a causative relationship between the assayed
DNA cleavage and the observed toxicity of VP-16. Indirect
evidence favouring this relationship has also been provided
by the work of other groups interested in the mechanism of
action of VP-16 (Glisson et al., 1986; Estey et al., 1987). This
is an important point if such observations are to serve as the
basis of new strategies for improving the therapeutic index of
clinical cancer therapy.
The effects of cycloheximide and aphidicolin on VP-16-in-
duced DNA cleavage in oestrogen-primed cells are in strong
agreement with those reported by Chow & Ross (1987) for
the effects of these inhibitors on enhanced VP-16-induced
cleavage seen in synchronised cultures released from
quiescence. The inhibitory effect of cycloheximide
documented in both reports indicates that the enhanced
drug-induced DNA cleavage witnessed in activated cell
cultures is dependent at some point on new protein
synthesis. This is perhaps not surprising given the very early
protein synthetic events detectable immediately following
stimulation (Figure Sa), events which presumably play an
important role in the sequential cascade of mitogenic acti-
vation. On the other hand, the lack of antagonism induced
by aphidicolin in both studies suggests that enhancement of
VP-16-induced DNA cleavage occurs predominantly, if not
exclusively, within activated GI-phase cells. This scenario is
clearly more attractive for the design of clinical trials based
on target cell stimulation than is a strategy dependent upon
highly schedule-specific administration of S-phase-active
drugs.
That the enhancement of VP-16-induced DNA cleavage
does indeed occur in Gl-phase cells is further supported by
the data presented in Figure 5, which shows that VP-16-
induced DNA cleavage is enhanced several hours prior to
enhancement of DNA synthesis. Since c-myc protein levels
are increased only two-fold by oestrogen stimulation of this
cell system - whereas numerous studies of synchronised cell
systems confirm a ten-fold increment in the expression of
this gene following release of cells from quiescence (Kelly et
al., 1983; Dean et al., 1986) - the possibility exists that only
a fraction of the T-47D cell population is activated by
oestrogen exposure. This hypothesis is consistent with the
relatively small increase in S-phase cells documented after
24h oestrogen exposure (Figure 5d). Furthermore, if only a
subpopulation of GI-phase cells is in fact activated by
oestrogen, the observed overall two-fold enhancement of VP-
16-induced DNA cleavage could represent a gross under-
estimate of true DNA cleavage enhancement in the putative
oestrogen-activated cell subset. Flow cytometric studies are
now underway to clarify this issue by examining the effect of
VP-16-induced DNA damage at the single-cell level.
There is now much evidence suggesting that most VP-16-
induced DNA cleavage revealed by alkali- or proteinase-
based DNA damage assays represents stabilised 'cleavable
complexes' of DNA and the intranuclear enzyme
topoisomerase II (Chen et al., 1984; Ross et al., 1984). The
importance of chromatin structure (addressed in Figure 4) in
mediating this type of DNA lesion has been highlighted by
the work of Udvardy & Schedl (1986). Absolute levels of
topoisomerase II have, moreover, recently been recognised to
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Figure 4 Influence of oestrogen on DNA and chromatin
structure in cells not exposed to VP-16: (a) Effect of oestrogen
on DNA double-strandedness as measured by either nucleoid
sedimentation or alkaline DNA unwinding. Up to 72h oestrogen
exposure (0) leads to no change in nucleoid sedimentation
compared to control (0). Samples pre-treated with oestrogen for
24h (-) show no change in the rate of alkaline DNA unwinding
when compared with ethanol-treated controls (A) over a 3h
unwinding period; (b) Influence of 24h oestrogen pretreatment
on DNA superhelicity as measured by ethidium bromide titration
of histone-depleted nucleoids. The amount of ethidium bromide
required to induce minimum sedimentation (i.e. minimal DNA
supercoiling) is not distinguishably different in oestrogen-treated
(0) and control (0) samples. Datum points are based on one of
two similar experiments; (c) Bleomycin-induced DNA scission as
an index of chromatin accessibility in oestrogen-treated (0) and
control (0) cells; (d) DNase II nicking as an index of chromatin
accessibility in freeze-thaw-permeabilised cells. 0, control cells;
*, oestrogen-treated cells.
be higher in proliferating than in quiescent cells (Heck &
Earnshaw, 1986). However, the report that enzyme levels (as
determined by immunoblotting) rise only in S- and G2-phase
cells following stimulation - even though enhancement of
VP-16-induced DNA cleavage is unaffected by inhibition of
DNA synthesis using aphidicolin (Chow & Ross, 1987) -
suggests that enzyme activation within GI-phase cells may
accompany cellular activation, a model supported by the
data presented here. Indeed, in vitro data have already
implicated phosphorylation (Ackerman et al., 1985),
poly(ADP-ribosyl)ation (Darby et al., 1985) and calcium-
mediated pathways (Osheroff & Zechiedrich, 1987) as
candidate mechanisms for topoisomerase II activation.
Hence the inhibition of VP-16-induced cleavage seen with
cycloheximide exposure could signify inhibited synthesis of a
molecule contributing to the process of enzyme activation,
rather than necessarily implicating inhibition of
topoisomerase II synthesis per se. We are currently exploring
these questions further by correlating other parameters of
topoisomerase II availability with VP-16-induced DNA
cleavage.
The findings presented here suggest that oestrogen
stimulation of asynchronously growing human breast cancer
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Figure 5 Timing of detectable events following commencement
of oestrogen exposure: (a) Increase in c-myc protein levels
measured at various time-points following stimulation. Datum
points are based on duplicate specimens; (b) Increase in VP-16-
induced DNA cleavage following 5pM VP-16 treatment; (c)
Increase in 3H-thymidine incorporation during oestrogen
stimulation. Standard errors are based on triplicate measure-
ments; (d) Oestrogen-stimulated increase in rate of cell-cycle
traverse. GI-phase emptying was determined for samples exposed
to either oestrogen or ethanol alone for the required period by
simultaneously treating samples with colcemid 60ngml-1. Since
this manoeuvre prevents mitotic cells re-entering GI, the rate at
which cells exit from Gl can be used as an index of the rate of
cell-cycle traverse. Control values at each time-point were
subtracted from those of oestrogen-treated samples to yield a net
percentage of Gl-phase cells exiting from Gl as a consequence
of oestrogen stimulation alone; (e) Effect of oestrogen
stimulation on cell-cycle redistribution as measured by absolute
increase in S-phase fraction relative to control. The percentage of
cells in S-phase was calculated by flow cytometric analysis. 0,
control cells; 0, oestrogen-treated cells.
cells is a clinically relevant strategy for improving the
therapeutic index of VP-16. Since drugs more commonly
used to palliate breast cancer- such as mitoxantrone - are
also known to interact with topoisomerase II (Crespi et al.,
1986), this strategy could be rationally combined with state-
of-the-art management regimens without recourse to po-
tentially confounding cell synchronisation protocols. A
clinical trial is now being designed to determine the empirical
value of this approach in patients with disseminated breast
cancer.
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